阿魏酸钠治疗糖尿病肾病的疗效及对患者肾间质纤维化及尿微量蛋白的影响

doi:10.3969/j.issn.1671-7171.2022.06.010

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1167 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To observe the effect of sodium ferulate on renal interstitial fibrosis and urinary microprotein in patients with diabetic nephropathy. 【Methods】A total of 100 patients with diabetic nephropathy treated in the two hospitals were divided into the observation group and the control group according to random number table method,with 50 cases in each group. The control group was given basic treatment such as routine hypoglycemic and antihypertensive treatment,,While the observation group was given sodium ferulate injection on the basic treatment of the control group. Patients in both groups received treatment for 2 weeks. The therapeutic effects of the two groups were observed. Angiotensin Ⅱ(Ang Ⅱ),connective tissue growth factor (CTGF),type Ⅳ collagen (CⅣ),type Ⅲ procollagen (PCⅢ),blood urea nitrogen (BUN),blood creatinine(SCr),β2-microglobulin(β2-MG) and urinary microalbumin (UmAlb) were measured before and 1 month after treatment. The drug adverse reactions of the two groups were counted. 【Results】The total effective rate in observation group was significantly higher than that in control group (P<0.05).The levels of Ang Ⅱ,CTGF,C Ⅳ and PC Ⅲ in the two groups after treatment were significantly lower than those before treatment (P<0.05). After treatment,the levels of Ang Ⅱ,CTGF,C Ⅳ and PC Ⅲ in the observation group were significantly lower than those in the control group (P<0.05).The levels of SCr,BUN,β2-MG and UmAlb in both groups after treatment were significantly lower than before treatment (P<0.05).And the levels of SCr,BUN,β2-MG and UmAlb in observation group were significantly lower than those in control group after treatment (P<0.05).There was no significant difference in adverse reactions between the two groups (P>0.05). 【Conclusion】Treatment of diabetic nephropathy with sodium ferulate can effectively reduce renal interstitial fibrosis and urinary microprotein index,and protect renal function.No obvious adverse drug reactions were seen,which is worthy of clinical promotion.

Key words： Diabetic Nephropathies/DT FERULIC ACID /PD Nephritis, Interstitial Albuminuria

Received: 19 January 2022

PACS:

R587.24

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MIAO Feng
	LUO Gai-ying

Cite this article:

MIAO Feng,LUO Gai-ying. Effect of Sodium Ferulate on Renal Interstitial Fibrosis and Urinary Microprotein in Diabetic Nephropathy[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 835-837.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.06.010 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I6/835

[1] PERCO P,MAYER G.Molecular,histological and clinical phenotyping of diabetic nephropathy:valuable complementary information?[J].Kid Int,2018,93(2):308-310.
[2] 唐建成,黄焕森,徐世元,等. 右美托咪定对糖尿病肾病患者肾移植围手术期血糖的影响[J].中国现代医学杂志,2019,29(7):113-116.
[3] 吕翠岩,张岩,贾晓蕾,等.参芪地黄汤化裁方结合西医常规疗法治疗Ⅳ期糖尿病肾病临床研究[J].国际中医中药杂志,2020,42(5):431-436.
[4] MILDER T Y,STOCKER S L,SAMOCHA-BONET D,et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease[J].Eur J Clin Pharmacol,2019,75(11):1481-1490.
[5] 中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):792-801.
[6] 王海燕. 肾脏病学[M]. 北京:人民卫生出版社,2008:1424-1425.
[7] 马爱景,姚曦. 雷公藤多苷片联合钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾病肾功能及蛋白尿水平影响研究[J].中华中医药学刊,2020,38(8):200-203.
[8] IR A,RSRAH A,RPA A,et al.Association between PPARγ rs1801282 polymorphism with diabetic nephropathy and type-2 diabetes mellitus susceptibility in south India and a meta-analysis-Science Direct[J].Nefrologia (Engl Ed),2020,40(3):287-298.
[9] QIN C.Clinical effect of sodium ferulate combined peritoneal dialysis in patients with end-stage diabetic nephropathy complicated with heart failure[J].J Math Med,2018,31(12):1841-1842.
[10] 张鹏,乔晞,乔海燕,等. 阿魏酸钠联合缬沙坦对糖尿病肾病患者的疗效及对肾脏纤维化的影响[J].现代生物医学进展,2020,20(11):2148-2151.
[11] 王利民,池文婕,王玮,等. 阿魏酸钠联合阿托伐他汀对糖尿病肾病患者肾间质纤维化及炎症因子的影响[J].海南医学院学报,2018,24(8):837-840.
[12] 施磊. 骨化三醇联合缬沙坦对糖尿病肾病肾素,血管紧张素及血管紧张素转换酶表达的影响[J].药物评价研究,2019,42(6):1189-1193.
[13] GERRITS T,ZANDBERGEN M,WOLTERBEEK R,et al.Endoglin promotes myofibroblast differentiation and extracellular matrix production in diabetic nephropathy[J].Int J Mol Sci,2020,21(20):7713.
[14] 杨莹,江军. 阿魏酸钠联合阿托伐他汀对糖尿病肾病患者临床疗效及肾间质纤维化指标的影响研究[J].四川医学,2018,39(8):888-891.
[15] 朱文婧,卓宇苗,梁钊雄,等. 阿魏酸哌嗪辅助治疗糖尿病肾病的效果及对患者肾功能,血液流变学指标的影响[J].海南医学,2020,31(7):835-837.